Share on StockTwits

Analysts at MLV & Co
lowered their price target on shares of Coronado Biosciences (NASDAQ:CNDO) from $16.50 to $15.00 in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock.

Shares of Coronado Biosciences (NASDAQ:CNDO) traded up 9.15% during mid-day trading on Monday, hitting $1.79. 282,215 shares of the company’s stock traded hands. Coronado Biosciences has a 52 week low of $1.25 and a 52 week high of $10.20. The stock has a 50-day moving average of $1.75 and a 200-day moving average of $2.14. The company’s market cap is $79.3 million.

Coronado Biosciences (NASDAQ:CNDO) last announced its earnings results on Monday, May 12th. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.01. On average, analysts predict that Coronado Biosciences will post $-0.75 earnings per share for the current fiscal year.

Coronado Biosciences, Inc is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.